By 2018, nearly half of all TMVR patients were going home the very next day. Outcomes for these patients have been consistently positive. 

Researchers tracked data from more than 54,000 adult patients with CLD who underwent PCI from 2004 to 2015.

Cardiogenic shock has been linked to a heightened risk of morbidity and mortality. TEER, it seems, may be able to help provide patients with some relief. 

The new analysis, published in JACC: Heart Failure, focused on patient data from the renowned COAPT trial. 

Declining elective PCI rates, a shift toward the outpatient setting and changes in the initial management of stable ischemic heart disease all appear to be responsible for the drop.

Women receive less evidence-based therapies for CAD, researchers found, but they have a better long-term survival advantage after undergoing PCI compared to men.

The authors tracked data from more than 400 SCAD patients, sharing their findings in Heart.

Rather than a binary choice—atherectomy or lithotripsy—the market for treating severely calcified lesions seems likely to evolve into a mixture of both technologies. That, in fact, is already occurring. One strategy gaining currency among interventionalists, particularly those in Europe, is to try a high-pressure balloon first in cases of moderately severe calcification and, if the device fails to fully expand, re-enter the vessel with atherectomy.